101830-90-4

Basic information

• Product Name: DIETHYL 2-[(2,4-DIFLUOROANILINO)METHYLENE]MALONATE
• Synonyms: DIETHYL 2-[(2,4-DIFLUOROANILINO)METHYLENE]MALONATE;1,3-diethyl 2-{[(2,4-difluorophenyl)amino]methylidene}propanedioate
• CAS NO: 101830-90-4
• Molecular Formula: C₁₄H₁₅F₂NO₄
• Molecular Weight: 299.27
• Mol File: 101830-90-4.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: DIETHYL 2-[(2,4-DIFLUOROANILINO)METHYLENE]MALONATE(CAS DataBase Reference)
• NIST Chemistry Reference: DIETHYL 2-[(2,4-DIFLUOROANILINO)METHYLENE]MALONATE(101830-90-4)
• EPA Substance Registry System: DIETHYL 2-[(2,4-DIFLUOROANILINO)METHYLENE]MALONATE(101830-90-4)

Safety Data

• Hazardous Substances Data: 101830-90-4(Hazardous Substances Data)

Upstream product

• 105-53-3 diethyl malonate 
• 367-25-9 2,4-difluorophenylamine 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 

Downstream Products

• 71083-11-9 ethyl 6,8-difluoro-4-hydroxyquinoline-3-carboxylate 

Relevant articles and documents

Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs

Our aim was to identify new multi-target compounds endowed with both anti-inflammatory and anti-bacterial activities for treatment of human infections. Diflunisal, a nonsteroidal anti-inflammatory agent, has recently been repurposed for its anti-virulence properties against methicillin-resistant Staphylococcus aureus. Effective synthesis of some aza-analogs of the anti-inflammatory drug diflunisal was carried out following the route involving key oxazole intermediates to obtain o- and m-hydroxypyridinecarboxylic acid derivatives. The newly synthesized diflunisal aza-analogs did not exhibit cytotoxic activity up to 80 μM and some of them exhibited anti-inflammatory activities, decreasing the levels of pro-inflammatory cytokines and prostaglandins induced by bacterial lipopolysaccharide in human primary macrophages. Ten of the diflunisal aza-analogs were found to have interesting antibacterial activity, sensitizing S. aureus, Streptococcus pyogenes, Enterococcus faecium, and Pseudomonas aeruginosa to the antibacterial effects of beta-lactam antibiotics and protein synthesis inhibitors.

Design, synthesis, and biological evaluation of novel quinoline derivatives as HIV-1 Tat-TAR interaction inhibitors

Thirty-two quinoline derivatives were designed and synthesized as HIV-1 Tat-TAR interaction inhibitors. All the compounds showed high antiviral activities in inhibiting the formation of SIV-induced syncytium in CEM174 cells. Nine of them with low cytotoxicities were evaluated by Tat dependent HIV-1 LTR-driven CAT gene expression colorimetric enzyme assay in human 293T cells, indicating effective inhibitory activities of blocking the Tat-TAR interaction. Molecular modeling experiments indicated that these compounds may inhibit Tat-TAR interaction by binding to Tat protein instead of TAR RNA.

Antibacterial activity of 6,8-disubstituted-quinolone-3-carboxylic acids

-